Viatris

Viatris Inc.
Company typePublic
ISINUS92556V1061
Industry
Predecessors
FoundedNovember 16, 2020; 3 years ago (2020-11-16)
Headquarters,
U.S.
Area served
Worldwide
Key people
  • Scott A. Smith (CEO)
Products
RevenueDecrease US$15.39 billion (2023)
Decrease US$766 million (2023)
Decrease US$54.7 million (2023)
Total assetsDecrease US$47.69 billion (2023)
Total equityDecrease US$20.47 billion (2022)
Number of employees
c. 38,000 (2023)
Subsidiaries
Websiteviatris.com
Footnotes / references
[1]

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.[2]

The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community.[3][4]

Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue.[5]

  1. ^ "Viatris Inc. 2023 Form 10-K Annual Report". U.S. Securities and Exchange Commission. February 28, 2024.
  2. ^ Gough, Paul J. (November 16, 2020). "After nearly 60 years, Mylan makes way for Viatris". American City Business Journals.
  3. ^ "Viatris picked as new name for a merged Mylan/Upjohn". Pittsburgh Post-Gazette. November 12, 2019.
  4. ^ Blankenship, Kyle (November 12, 2019). "Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before?". FiercePharma.
  5. ^ "Fortune: Viatris Company Profile, News, Rankings". Fortune.com. Fortune. Retrieved June 2, 2021.